SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Versant Venture Management, LLC

CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877

Reported Value
$202.0B
Q4 2018
Positions
10
Filings on Record
30
2019–present window
Filed
Jan 22, 2019
original filing

Summary

Versant Venture Management, LLC reported $202.0B in U.S.-listed holdings across 10 positions for Q4 2018.

The portfolio is heavily concentrated: Crispr Therapeutics alone accounts for 51.0% of reported value.

Portfolio Metrics

Top-10 Concentration
+100.0%
share of reported value
Largest Position
+51.0%
Crispr Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $202.0BQ4 ’18Q1 ’19: $303.6BQ2 ’19: $343.2BQ3 ’19: $258.5BQ4 ’19: $331.8BQ4 ’19Q1 ’20: $364.6BQ2 ’20: $696.1BQ4 ’20: $963MQ1 ’21: $513MQ1 ’21Q2 ’21: $302MQ3 ’21: $242MQ4 ’21: $187MQ1 ’22: $100MQ1 ’22Q2 ’22: $65MQ3 ’22: $59MQ4 ’22: $48MQ1 ’23: $48MQ1 ’23Q2 ’23: $84MQ3 ’23: $188MQ4 ’23: $389MQ1 ’24: $103MQ1 ’24Q2 ’24: $77MQ3 ’24: $64MQ4 ’24: $87MQ1 ’25: $60MQ1 ’25Q2 ’25: $82MQ3 ’25: $212MQ4 ’25: $151MQ1 ’26: $141MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Other: 54.5%Common Stock: 45.5%
  • Other · 54.5% · $110.1B
  • Common Stock · 45.5% · $91.9B

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
CRISPR Therapeutics AGNEW+3.61M3.61M+$103.1B$103.1B
VCYTVeracyte, Inc.NEW+3.62M3.62M+$45.5B$45.5B
BOLDEURAudentes Therapeutics, Inc.NEW+1.20M1.20M+$25.7B$25.7B
OCULOcular Therapeutix, Inc.NEW+2.22M2.22M+$8.8B$8.8B
CymaBay Therapeutics, Inc.NEW+1.08M1.08M+$8.5B$8.5B
Second Sight Medical Products, Inc.NEW+4.49M4.49M+$4.0B$4.0B
ImmuneDesign Corp.NEW+2.21M2.21M+$2.9B$2.9B
CLVSEURClovis Oncology, Inc.NEW+101.9K101.9K+$1.8B$1.8B

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

10 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CRISPR Therapeutics AGCommon Stock51.04%$103.1B3.61M
2VCYTVeracyte, Inc.history →Common Stock22.52%$45.5B3.62M
3BOLDEURAudentes Therapeutics, Inc.history →Common Stock12.71%$25.7B1.20M
4OCULOcular Therapeutix, Inc.history →Common Stock4.36%$8.8B2.22M
5CymaBay Therapeutics, Inc.Common Stock4.23%$8.5B1.08M
6Second Sight Medical Products, Inc.Common Stock1.97%$4.0B4.49M
7ImmuneDesign Corp.Common Stock1.42%$2.9B2.21M
8CLVSEURClovis Oncology, Inc.history →Common Stock0.91%$1.8B101.9K
9AKAOQAchaogen, Inc.history →Common Stock0.78%$1.6B1.28M
10OpGen, Inc.Common Stock0.07%$133M102.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$141M8May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$151M7Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$212M9Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$82M8Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$60M7May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$87M7Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$64M6Nov 8, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M8Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$103M7May 3, 202413F-HRchanges · EDGAR ↗
Q4 2023$389M7Feb 8, 202413F-HRchanges · EDGAR ↗
Q3 2023$188M8Nov 3, 202313F-HRchanges · EDGAR ↗
Q2 2023$84M8Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$48M7May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$48M7Feb 9, 202313F-HRchanges · EDGAR ↗
Q3 2022$59M8Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$65M8Aug 11, 202213F-HRchanges · EDGAR ↗
Q1 2022$100M10May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$187M10Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$242M11Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$302M11Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$513M11May 7, 202113F-HRchanges · EDGAR ↗
Q4 2020$963M12Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020Under review11Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$696.1B12Jul 20, 202013F-HRchanges · EDGAR ↗
Q1 2020$364.6B9Apr 28, 202013F-HRchanges · EDGAR ↗
Q4 2019$331.8B7Jan 21, 202013F-HRchanges · EDGAR ↗
Q3 2019$258.5B8Oct 8, 201913F-HRchanges · EDGAR ↗
Q2 2019$343.2B9Jul 12, 201913F-HRchanges · EDGAR ↗
Q1 2019$303.6B9Apr 5, 201913F-HRchanges · EDGAR ↗
Q4 2018$202.0B10Jan 22, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.